Vikram Arora
Vikram Arora has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Anthony M. Klos
Grifols Bioscience Research Group, 85 TW Alexander Drive, Research Triangle Park, NC, 27709, USA
1 shared publication- Constantinos P Tsipis
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA
1 shared publication - G McLeod Taylor
Research and Pre-clinical Development, Grifols Therapeutics, Inc., Research Triangle Park, North Carolina, USA
1 shared publication George Taylor
Grifols Bioscience Research Group, 85 TW Alexander Drive, Research Triangle Park, NC, 27709, USA
1 shared publicationJeffrey Price
Grifols Bioscience Research Group, 85 TW Alexander Drive, Research Triangle Park, NC, 27709, USA
1 shared publicationJohn Lang
Grifols Bioscience Research Group, 85 TW Alexander Drive, Research Triangle Park, NC, 27709, USA
1 shared publication
Latest Publications
- Open Access
- 16 May 2012
- Published by Springer Nature in Experimental & Translational Stroke Medicine
- Vol. 4 (1) , 10
Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke
Tissue type plasminogen activator is the only approved thrombolytic agent for the treatment of ischemic stroke. However, it carries the disadvantage of a 10-fold increase in symptomatic and asymptomatic intracranial hemorrhage. A safer thrombolytic agent may improve patient prognosis and increase patient participation in thrombolytic treatment. A novel direct-acting thrombolytic agent, Δ(K2-K5) plasmin, promising an improved safety profile was examined for safety in the snare ligature model of stroke in the rat.
- 16 May 2012
- Published by Springer Nature in Experimental & Translational Stroke Medicine
- Vol. 4 (1) , 10
Open AccessSafety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke
Tissue type plasminogen activator is the only approved thrombolytic agent for the treatment of ischemic stroke. However, it carries the disadvantage of a 10-fold increase in symptomatic and asymptomatic intracranial hemorrhage. A safer thrombolytic agent may improve patient prognosis and increase patient participation in thrombolytic treatment. A novel direct-acting thrombolytic agent, Δ(K2-K5) plasmin, promising an improved safety profile was examined for safety in the snare ligature model of stroke in the rat.